1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Regulatory Overhang Hurts Torrent

Dahej Unit Heads For Re-inspection By Mid-2020

 
• By Vibha Ravi

Torrent has tempered US growth expectations while it plans to put its Dahej, Indrad and Levittown plants up for FDA inspection in 2020. Meanwhile, products launched in India, including remoglifozin in-licensed from Glenmark, have shown an encouraging uptake.

SC1806_Hurdles_447668500 _1200.jpg
Torrent Has To Clear Several Hurdles To Get Back On Growth Path • Source: Shutterstock

After regulatory action, procedural hurdles and a product rationalization exercise combined to dent Torrent Pharmaceuticals’ revenues in the third quarter this fiscal year, the company has tamped down expectations for fiscal 2021. The company reported revenues of INR19.66bn ($276m) for the quarter ended 31 December, a 4% drop from the corresponding period last fiscal. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.

Samsung Bioepis Grows After US Launches

 
• By Dave Wallace

Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 
• By Urtė Fultinavičiūtė

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

Teva Crib Sheet Reveals Uzedy, Lenalidomide Expectations Ahead Of Q1

 
• By Dean Rudge

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.

More from Business

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.

How To Make The Most Of Your GGB Awards Entries

 
• By Dave Wallace

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

Denosumab Race Heats Up In Europe With Eight More Nods

 
• By Dave Wallace

Denosumab competition is heating up in Europe, with four more companies this month gaining EMA endorsements for their Prolia and Xgeva biosimilar rivals.